Cargando…

Physiologic Tailoring of Treatment in Resistant Hypertension

Resistant hypertension is a major opportunity for prevention of cardiovascular disease. Despite widespread dissemination of consensus guidelines, most patients are uncontrolled with approaches that assume that all patients are the same. Causes of resistant hypertension include 1) non-compliance 2) c...

Descripción completa

Detalles Bibliográficos
Autor principal: Spence, J. David
Formato: Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd. 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892077/
https://www.ncbi.nlm.nih.gov/pubmed/21532778
http://dx.doi.org/10.2174/157340310791162695
_version_ 1782182922251403264
author Spence, J. David
author_facet Spence, J. David
author_sort Spence, J. David
collection PubMed
description Resistant hypertension is a major opportunity for prevention of cardiovascular disease. Despite widespread dissemination of consensus guidelines, most patients are uncontrolled with approaches that assume that all patients are the same. Causes of resistant hypertension include 1) non-compliance 2) consumption of substances that aggravate hypertension (such as salt, alcohol, nonsteroidal anti-inflammatory drugs, licorice, decongestants) and 3) secondary hypertension. Selecting the appropriate therapy for a patient depends on finding the cause of the hypertension. Once rare causes have been eliminated (such as pheochromocytoma, licorice, adult coarctation of the aorta), the cause will usually be found by intelligent interpretation (in the light of medications then being taken) of plasma renin and aldosterone. If stimulated renin is low and the aldosterone is high, the problem is primary aldosteronism, and the best treatment is usually aldosterone antagonists (spironolactone or eplerenone; high-dose amiloride for men where eplerenone is not available). If the renin is high, with secondary hyperaldosteronism, the best treatment is angiotensin receptor blockers or aliskiren. If the renin and aldosterone are both low the problem is over-activity of renal sodium channels and the treatment is amiloride. This approach is particularly important in patients of African origin, who are more likely to have low-renin hypertension.
format Text
id pubmed-2892077
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Bentham Science Publishers Ltd.
record_format MEDLINE/PubMed
spelling pubmed-28920772011-05-01 Physiologic Tailoring of Treatment in Resistant Hypertension Spence, J. David Curr Cardiol Rev Article Resistant hypertension is a major opportunity for prevention of cardiovascular disease. Despite widespread dissemination of consensus guidelines, most patients are uncontrolled with approaches that assume that all patients are the same. Causes of resistant hypertension include 1) non-compliance 2) consumption of substances that aggravate hypertension (such as salt, alcohol, nonsteroidal anti-inflammatory drugs, licorice, decongestants) and 3) secondary hypertension. Selecting the appropriate therapy for a patient depends on finding the cause of the hypertension. Once rare causes have been eliminated (such as pheochromocytoma, licorice, adult coarctation of the aorta), the cause will usually be found by intelligent interpretation (in the light of medications then being taken) of plasma renin and aldosterone. If stimulated renin is low and the aldosterone is high, the problem is primary aldosteronism, and the best treatment is usually aldosterone antagonists (spironolactone or eplerenone; high-dose amiloride for men where eplerenone is not available). If the renin is high, with secondary hyperaldosteronism, the best treatment is angiotensin receptor blockers or aliskiren. If the renin and aldosterone are both low the problem is over-activity of renal sodium channels and the treatment is amiloride. This approach is particularly important in patients of African origin, who are more likely to have low-renin hypertension. Bentham Science Publishers Ltd. 2010-05 /pmc/articles/PMC2892077/ /pubmed/21532778 http://dx.doi.org/10.2174/157340310791162695 Text en © 2010 Bentham Science Publishers Ltd. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Spence, J. David
Physiologic Tailoring of Treatment in Resistant Hypertension
title Physiologic Tailoring of Treatment in Resistant Hypertension
title_full Physiologic Tailoring of Treatment in Resistant Hypertension
title_fullStr Physiologic Tailoring of Treatment in Resistant Hypertension
title_full_unstemmed Physiologic Tailoring of Treatment in Resistant Hypertension
title_short Physiologic Tailoring of Treatment in Resistant Hypertension
title_sort physiologic tailoring of treatment in resistant hypertension
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892077/
https://www.ncbi.nlm.nih.gov/pubmed/21532778
http://dx.doi.org/10.2174/157340310791162695
work_keys_str_mv AT spencejdavid physiologictailoringoftreatmentinresistanthypertension